Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Nimotuzumab, EBRT combined with brachytherapy.
- Who it may be relevant to
- Registry conditions: Cervical Squamous Cell Carcinoma. Basic parameters: from 65 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Perspective, Multi-center, Single Arm Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma
Overview
To evaluate the efficacy and safety of Nimotuzumab combined with IMRT in elder patients with locally advanced cervical squamous cell carcinoma
Detailed description
This is a perspective, multi-center, open-label and single arm study.
Interventions
- Drug Nimotuzumab
Patients receive Nimotuzumab: 200mg, intravenous infusion, weekly for 6 weeks. - Radiation EBRT combined with brachytherapy
IMRT/VMAT are adopted. A total dose of 45-50.4 Gy, 1.8\~2.0Gy/f, 25\~ 28F in pelvic and/or extension filed. For patients with metastasis in pelvic lymph node and abdominal para-aortic lymph node, the dose of radiation in local lesion will be increased to 60\~66Gy. For patients at stage IIIB, concurrent radiation will be given in parametrial extension or in the late course the dose will be increased to 60Gy. Brachytherapy: Three dimensional high dose rate brachytherapy is used with HR-CTV D90 cu
Primary outcome measures
- 3-year disease-free survival(DFS) [Time frame: up to 3 years]
Secondary outcome measures (7)
- Complete response rate(CRR) [Time frame: 3 months later after treatment]
- Objective response rate(ORR) [Time frame: 3 months later treatment]
- 3-year overall survival(OS) [Time frame: up to 3 years]
- The change of tumor related markers [Time frame: up to 3 years]
- The change of cervical tumor [Time frame: At diagnosis and before brachytherapy]
- QUALITY OF LIFE(QoL) [Time frame: up to 3 years]
- SAFETY [Time frame: up to 3 years]
Eligibility criteria
Inclusion criteria
- Age≥65 years old
- Histologically confirmed primary cervical squamous cell carcinoma in stage IB3-IVA (FIGO 2018)
- At least one measurable lesion according to RECIST 1.1 guideline
- Patients are intolerant to or refuse chemotherapy.
- No serious hematopoietic dysfunction, nor abnormal heart, lung, liver and kidney function, nor immunity deficiency. And the results of lab test meet the following criteria:
Hemoglobin ≥90g/L Absolute count of neutrophils≥2×109/L orwhite blood cell count≥4.0×109/L； Platelet count≥100×109/L； AST≤2.5×ULN ALT≤2.5×ULN TBIL≤1.5×ULN；
Serum creatinine≤1.5×ULN or CrCl> 60 mL/min(according toCockcroft-Gault):
Serum creatinine≤1.5×ULN Female CrCl=(140-Age)×Weight（kg）×0.85 / (72×Scr mg/dl)
- ECOG score 0-2
- Expectancy of life is at least 3 months.
- Eligible for pelvic MRI examination.
- The patients voluntarily received nimotuzumab combined with radiotherapy.
- Patients can comply with the protocol and are willing to sign informed consent.
Exclusion criteria
- Patients who have received treatment for cervical cancer, including surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy
- Patients who have bilateral ureteral obstruction, who cannot be placed ureteral stents or perform pyelostomy.
- Patients with rectovaginal fistula/vaginovesical fistula/uncontrolled vaginal bleeding or with fistula risk.
.4)Patients infected with HIV. 5)Active hepatitis B (HBV DNA quantitative test results exceed the detection threshold), or HCV infection (HCV RNA quantitative test results exceed the detection threshold) 6)Patients with severe underlying disease that makes it possible to safely receive the treatment. And the severe underlying disease include but not limited to active infections requiring systemic medication, decompensated heart failure (NYHA grade III and IV), unstable angina pectoris, and acute myocardial infarction occurred within the first 3 months of enrollment.
7)Patients with a history of prior malignancy other than cured basal cell carcinoma of the skin.
8)Patients with Crohn's disease and ulcerative colitis. 9)Patients are allergic to Nimotuzumab or its compounds. 10)Patients with neurological or psychiatric abnormalities that affect cognitive ability.
11)Intracavitary brachytherapy cannot be performed that was assessed by the investigator.
12)Other factors were assessed by investigators to be unsuitable to this study.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Peking University 3rd Hospital — Beijing
Identifiers
NCT: NCT04976478 · ChiECRCT20210238